Artemether Attenuates Aβ25-35-Induced Cognitive Impairments by Downregulating Aβ, BACE1, mTOR and Tau Proteins.

BACKGROUND Alzheimer's disease (AD) is clinically characterized as a progressive cognitive impairment and behavioral disorder. Pathological hallmarks of AD include extracellular senile plaques (SPs), intracellular neurofibrillary tangles (NFTs) and massive neuronal loss. Although the exact cause of AD is not well understood, a mounting body of evidence has demonstrated that the pathogenesis of AD is associated with oxidative stress, neu-roinflammation, and amyloid beta (Aβ) induced neural apoptosis. Moreover, overexpression of β-secretase 1 (BACE1), Aβ, mammalian target of rapamycin (mTOR), and Tau proteins are closely related to cognitive symptoms in AD. Studies have demonstrated that artemether, an antimalarial drug with acceptable side effects, possesses protective effects against neuroinflammation and oxidative stress. Importantly, artemether can easily penetrate the blood brain barrier, thereby representing an ideal drug candidate for AD treatment. METHODS The effect of artemether on memory protection and the associated molecular mechanisms were investigated in an Aβ25-35 induced cognitive impairments rat model. RESULTS Results of the in vivo study showed that oral administration of artemether significantly attenuated Aβ25-35-induced cognitive impairment in rats. Results of the in vitro study revealed that artemether significantly downregulated the endogenous expression of Aβ, BACE1, mTOR, and Tau proteins in N2a cells. CONCLUSIONS The beneficial effect of artemether against Aβ 25-35-induced cognitive impairments was attributable to the downregulation of the expression of Aβ, BACE1, mTOR, and Tau proteins, suggesting the potential of artemether as an effective, neuronal protective, and multi-targeted drug candidate for AD treatment.